RIG
ABBV icon

RiverFront Investment Group’s AbbVie ABBV Stock Holding History

RiverFront Investment Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
59,624
+21,407
+56% +$4.61M 0.2% 70
2026
Q1 		$8.31M Buy
38,217
+7,640
+25% +$1.69M 0.13% 78
2025
Q4 		$6.99M Buy
30,577
+9,005
+42% +$2.05M 0.12% 73
2025
Q3 		$4.99M Buy
21,572
+12,148
+129% +$2.47M 0.09% 83
2025
Q2 		$1.75M Sell
9,424
-490
-5% -$91.1K 0.03% 114
2025
Q1 		$2.08M Buy
9,914
+6,433
+185% +$1.25M 0.05% 101
2024
Q4 		$619K Buy
3,481
+337
+11% +$62K 0.01% 148
2024
Q3 		$621K Buy
3,144
+1,098
+54% +$205K 0.01% 135
2024
Q2 		$351K Sell
2,046
-26
-1% -$4.31K 0.01% 136
2024
Q1 		$377K Sell
2,072
-60,186
-97% -$10.4M 0.01% 102
2023
Q4 		$9.65M Buy
62,258
+2,464
+4% +$359K 0.3% 52
2023
Q3 		$8.91M Buy
59,794
+5,478
+10% +$804K 0.32% 50
2023
Q2 		$7.32M Buy
54,316
+2,163
+4% +$317K 0.24% 54
2023
Q1 		$8.31M Buy
52,153
+3,133
+6% +$479K 0.29% 50
2022
Q4 		$1.64M Sell
49,020
-6,651
-12% -$1.02M 0.37% 53
2022
Q3 		$7.94M Sell
55,671
-3,093
-5% -$444K 0.3% 49
2022
Q2 		$9M Buy
+58,764
New +$8.98M 0.34% 49

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RiverFront Investment Group's ABBV Position: Q2 2026 in Review

RiverFront Investment Group increased its AbbVie (ABBV) stake by 56% in Q2 2026, buying an estimated $4.61M and bringing the position to 59,624 shares worth $15M. The position accounts for 0.2% of the portfolio, ranked #70.

RiverFront Investment Group first reported a position in ABBV in Q2 2022 and has held it in 17 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • RiverFront Investment Group held 59,624 shares of AbbVie worth $15M as of Q2 2026.
  • RiverFront Investment Group bought 21,407 AbbVie shares in Q2 2026, an estimated $4.61M.
  • AbbVie made up 0.2% of RiverFront Investment Group's portfolio in Q2 2026, its #70 holding.
  • RiverFront Investment Group first reported a position in AbbVie in Q2 2022 and has held it in 17 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on RiverFront Investment Group's 13F filing for Q2 2026, filed 29 Jul 2026.